Evidence mapPaperPMID 42566012Full record

ArticleAbdominal radiology (New York)2026

Local recurrence in rectal cancer: from detection to structured reporting.

Mohamed A Hamza, Valesca Bizinoto, Renata Vidal Leão, Ahmed Omar El Sadane Rabie, Shannon P Sheedy, Rodrigo Sanford, Mike L Wells, Yashant Aswani, Patrick J Navin, Bernardo Salvajoli and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohamed A HamzaDepartment of Radiology, Mayo Clinic, Rochester, USA.
Valesca BizinotoDepartment of Radiology, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Renata Vidal LeãoDepartment of Radiology, University of Iowa, Iowa City, USA.
Ahmed Omar El Sadane RabieDepartment of Radiology, Mayo Clinic, Rochester, USA.
Shannon P SheedyDepartment of Radiology, Mayo Clinic, Rochester, USA.
Rodrigo SanfordDepartment of Radiology, University of Iowa, Iowa City, USA.
Mike L WellsDepartment of Radiology, Mayo Clinic, Rochester, USA.
Yashant AswaniDepartment of Radiology, University of Iowa, Iowa City, USA.
Patrick J NavinDepartment of Radiology, Mayo Clinic, Rochester, USA.
Bernardo SalvajoliDepartment of Radiation Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Cameron M CallaghanDepartment of Radiation Oncology, Mayo Clinic, Rochester, USA.
Carlos Frederico Sparapan MarquesDepartment of Gastroenterology Colorectal Division, Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Eric J DozoisDepartment of Surgery, Mayo Clinic, Rochester, USA.
Joel G FletcherDepartment of Radiology, Mayo Clinic, Rochester, USA.
Natally HorvatDepartment of Radiology, Mayo Clinic, Rochester, USA. Horvat.Natally@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in total mesorectal excision and neoadjuvant therapy, locally recurrent rectal cancer remains a clinically important source of pelvic morbidity and cancer-related mortality, affecting approximately 2-10% of the treated patients. Most recurrences develop within three years of surgery and often arise near the surgical bed, where fibrosis and distorted anatomy can delay detection. Early recognition is critical because complete R0 resection offers the best chance of durable disease control and survival. Imaging provides the anatomic and functional information required to diagnose pelvic recurrence and guide multidisciplinary management. Contrast-enhanced CT of the chest, abdomen, and pelvis is typically used for routine surveillance and often provides the first radiologic suspicion of recurrence, particularly by detecting distant metastases or pelvic disease. However, CT has a limited ability to distinguish viable tumor from postoperative or post-radiation fibrosis in the pelvis. Suspicious or equivocal CT findings should therefore prompt high-resolution pelvic MRI using a recurrence protocol. MRI, including T2-weighted, diffusion-weighted, and contrast-enhanced sequences, is the preferred modality for local characterization and staging. MRI helps differentiate recurrent tumor from fibrosis, defines locoregional extent, and evaluates involvement of adjacent structures that directly influence resectability. For posterior compartment recurrence, dedicated musculoskeletal MRI of the sacrum may further delineate marrow infiltration, cortical involvement, sacral foraminal invasion, and nerve root extension, supporting surgical planning and margin assessment. FDG-PET/CT is useful when CT or MRI findings are equivocal and for excluding unsuspected metastatic disease, although mucinous tumors, chronic inflammation, and small-volume disease may reduce sensitivity. Hybrid FDG-PET/MRI has shown promising performance in detecting pelvic recurrence in small studies and may reduce equivocal interpretations; however, its incremental value in evaluating perineural spread and altering surgical management has not been established. This review summarizes recurrence patterns, optimal multimodality imaging techniques, pitfalls, structured reporting, and emerging applications of functional imaging, radiomics, and artificial intelligence in the individualized management of these patients.

Indexed as

Computed TomographyMagnetic Resonance ImagePelvic ExenterationPET-CTRectal CancerRecurrence

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.